Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Puma Biotechnology
(NQ:
PBYI
)
5.010
+0.020 (+0.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
290,457
Open
4.920
Bid (Size)
5.050 (4)
Ask (Size)
5.200 (3)
Prev. Close
4.990
Today's Range
4.900 - 5.080
52wk Range
2.130 - 7.730
Shares Outstanding
47,509,765
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
Today 7:13 EDT
Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy.
Via
InvestorPlace
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
April 18, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Performance
YTD
+10.72%
+10.72%
1 Month
+6.71%
+6.71%
3 Month
+6.37%
+6.37%
6 Month
+117.83%
+117.83%
1 Year
+88.35%
+88.35%
More News
Read More
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
March 20, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Earnings Scheduled For February 29, 2024
February 29, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
March 19, 2024
Via
Benzinga
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
February 29, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 27, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
February 22, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 14, 2024
Via
Benzinga
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
February 13, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
3 small-cap biotechs with potential breakthroughs in 2024
February 06, 2024
Via
MarketBeat
Topics
Bankruptcy
Exposures
Financial
Legal
3 Strong Buy Stocks Under $5: January 2024
January 31, 2024
Via
InvestorPlace
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
January 11, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
December 11, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Third Quarter 2023 Financial Results
November 02, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
October 19, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
October 14, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
September 21, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
August 08, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Second Quarter Financial Results
August 03, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.